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ABSTRACT
Across vertebrate genomes methylation of cytosine
residues within the context of CpG dinucleotides is
a pervasive epigenetic mark that can impact gene
expression and has been implicated in various de-
velopmental and disease-associated processes.
Several biochemical approaches exist to profile
DNA methylation, but recently an alternative
approach based on profiling non-methylated CpGs
was developed. This technique, called CxxC affinity
purification (CAP), uses a ZF-CxxC (CxxC) domain to
specifically capture DNA containing clusters of
non-methylated CpGs. Here we describe a new
CAP approach, called biotinylated CAP (Bio-CAP),
which eliminates the requirement for specialized
equipment while dramatically improving and sim-
plifying the CxxC-based DNA affinity purification.
Importantly, this approach isolates non-methylated
DNA in a manner that is directly proportional to
the density of non-methylated CpGs, and discrimin-
ates non-methylated CpGs from both methylated
and hydroxymethylated CpGs. Unlike conventional
CAP, Bio-CAP can be applied to nanogram
quantities of genomic DNA and in a magnetic
format is amenable to efficient parallel processing
of samples. Furthermore, Bio-CAP can be applied to
genome-wide profiling of non-methylated DNA
with relatively small amounts of input material.
Therefore, Bio-CAP is a simple and streamlined
approach for characterizing regions of the
non-methylated DNA, whether at specific target
regions or genome wide.
INTRODUCTION
Cytosine methylation within the context of CpG dinucleo-
tides is the most prevalent modiﬁcation to vertebrate
DNA and represents the best understood epigenetic modi-
ﬁcation [reviewed in ref. (1)]. Methylated CpGs dominate
the vertebrate genomic landscape, occurring within both
intragenic and intergenic regions (2). Despite pervasive
CpG methylation, vertebrate genomes are punctuated by
DNA elements called CpG islands (CGIs) that have a high
concentration of CpGs that exist in a predominantly
non-methylated state (3,4). Importantly, CGIs are
associated with  70% of annotated genes suggesting
that they play an important functional role at gene regu-
latory elements (5,6).
The methylation status of CpG dinucleotides, especially
within the context of CGI promoters, has implications for
the gene expression. The most striking examples of this
involve acquisition of DNA methylation at CGI pro-
moters, which is usually coupled to silencing of the
associated gene. This phenomenon has been documented
during cellular differentiation and certain disease states,
most notably cancer. For example, a broad number
of cancers are associated with the acquisition of DNA
methylation at CGI promoters of tumour suppressor
genes (7–9). DNA methylation is also implicated in
X chromosome inactivation, during which hundreds of
CGIs on the X chromosome acquire DNA methylation,
while genomic imprinting mechanisms often involve dif-
ferential CGI methylation between maternal and paternal
alleles (10,11).
The links between DNA methylation and gene expres-
sion have provoked tremendous interest in studying CpG
methylation states and consequently a broad range of
techniques have been developed for this purpose
[reviewed in ref. (12)]. These include bisulﬁte conversion
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uracil, followed by interrogation via sequencing-based
approaches (bisulﬁte sequencing). Bisulﬁte sequencing
reveals cytosine methylation states at base pair resolution
and is unparalleled in this regard. Although bisulﬁte con-
version has been coupled to massively parallel sequencing
to yield genome-wide methylation proﬁles at a base pair
resolution (2,13), this is an extremely costly endeavour due
to the depth of sequencing required.
Techniques based on afﬁnity capture of methylated
DNA, notably methylated DNA immunoprecipitation
(MeDIP) and methylated DNA capture by afﬁnity puriﬁ-
cation (MethylCap), have proved of utility in DNA
methylation studies [reviewed in refs (12,14)]. These
methods have been combined with massively parallel
sequencing to yield genome-wide methylation proﬁles,
albeit at lower resolution than those obtained with
bisulﬁte sequencing approaches (15). Given the abundance
of DNA methylation, even methyl-CpG afﬁnity appro-
aches can require an economically prohibitive sequencing
depth to obtain accurate locus-speciﬁc DNA methylation
proﬁles (16). Using a zinc ﬁnger CxxC (CxxC) domain
that speciﬁcally recognizes non-methylated CpGs (17),
Bird and colleagues (18) recently developed a clever ap-
proach based on CxxC afﬁnity puriﬁcation (CAP) to al-
ternatively proﬁle non-methylated DNA. Given that only
1–2% of a typical vertebrate genome is non-methylated,
the CAP assay speciﬁcally recovers a much smaller
genomic fraction than methylated DNA afﬁnity appro-
aches yet retains the capacity to differentiate between
methylated and non-methylated CpG dinucleotides.
Using CAP followed by massively parallel sequencing,
non-methylated regions of the genome can be proﬁled
with comparatively low sequencing depth (18,19).
The conventional CAP assay works by manually frag-
menting the genome into regions containing intact
non-methylated DNA followed by application of the
DNA material to an automated chromatography system
encompassing a CxxC afﬁnity resin. Non-methylated
DNA binds to the resin and is eluted using either a
linear salt gradient or step gradient. During the chroma-
tographic run, fractions are automatically collected,
analysed and combined to isolate puriﬁed non-methylated
DNA. The existing CAP technique has several limitations
that make it inaccessible to some research groups and im-
practical for certain experimental scenarios. For example,
the incorporation of an automated chromatography step
requires access to a high-resolution chromatographic
system. Since this approach uses a 1ml chromatography
column packed with the afﬁnity resin, it requires large
amounts of the recombinant CxxC module (60mg)
(18,19). Processing samples via the 1ml column conﬁgur-
ation necessitates large elution volumes that subsequently
require DNA precipitation prior to PCR or sequencing
analysis. These large elution volumes and DNA
handling steps (during which there is the potential for
loss of DNA) in turn mean that the CAP assay requires
large amounts of input DNA, restricting the utility of this
approach in instances where the amount of DNA material
available is limiting (for example rare cell types or
valuable patient samples). From a pragmatic standpoint,
the DNA preparation, chromatography and processing
time mean that CAP is labour-intensive, time-consuming
and not amenable to parallel processing of multiple DNA
samples.
To overcome many of the limitations inherent to con-
ventional CAP, we have engineered a completely new
CAP approach, called biotinylated CAP (Bio-CAP),
which is fast, simple, requires no specialized equipment
and efﬁciently isolates the non-methylated regions of gen-
omic DNA. Furthermore, we demonstrate that Bio-CAP
can be applied to very small quantities of genomic DNA,
which is adaptable to parallel processing, and provides
material suitable for massively parallel sequencing-based
genome-wide analysis of non-methylated DNA.
MATERIALS AND METHODS
DNA constructs
A ZF-CxxC construct encoding amino acids 600–750
of human KDM2B was PCR ampliﬁed from a
human KDM2B cDNA and engineered to encode a
C-terminal avi-tag. The PCR product was inserted
via ligation-independent cloning into a pNIC28 prokary-
otic expression vector that has been modiﬁed to express an
N-terminal 6-his tag followed by a tobacco etch virus
(TEV) protease cleavage site as described before (20).
The sequence integrity of the resulting construct was
veriﬁed by sequencing.
Protein expression and puriﬁcation
The CxxC-avi protein was expressed by freshly transform-
ing a BL21 expression strain carrying the pRAR2 plasmid.
The 4 L cultures were grown in 2 TB supplemented with
0.25mM ZnCl2 and grown to an OD600 of 0.6 at 37 C.
The culture was then cooled to 30 C and expression was
induced with 1mM IPTG for 3h. After 3h, the cultures
were pelleted and the CxxC-avi protein was isolated in
batch by Ni-NTA-mediated puriﬁcation as described pre-
viously (Klose and Bird, 2004). The peak elution fractions
from the Ni-NTA puriﬁcations were pooled and digested
overnight at 4 C with His-tagged TEV protease. The fol-
lowing day the protein was desalted to remove the imid-
azole and reapplied to a Ni-NTA column to remove the
cleaved tag and TEV protease. The cleaved CxxC-avi
protein was then desalted into 10mM Tris pH 8.0 contain-
ing 250mM potassium glutamate in preparation for
in vitro biotinylation. The yield of pure CxxC-avi protein
after this step was 16mg. In vitro biotinylation was carried
out by adding His-tagged recombinant BirA to the protein
and supplementing the reaction with 10mM ATP, 10mM
Mg(OAc)2 and 50mM D-biotin. The reaction was allowed
to proceed overnight. The efﬁciency of biotinylation was
veriﬁed by mass spectrometry prior to and after in vitro
biotinylation. The following day the reaction was supple-
mented with 20mM imidazole and applied to Ni-NTA
resin to remove the His-tagged BirA ligase. The CxxC-
avi protein was then desalted into 20mM HEPES pH
7.9, 150mM KCl, 0.5mM dithiothreitol (DTT) and 10%
glycerol and stored aliquoted at  80 C. The ﬁnal yield of
pure biotinylated CxxC-avi protein from 4 L was 6mg.
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Electrophoretic mobility shift assay (EMSA)
EMSA probes were generated and labelled as previously
described (Blackledge et al., 2010). EMSA was also per-
formed as previously described with samples analysed on a
1.3% agarose gel.
Cell culture
Murine V6.5 embryonic stem (ES) cells [C57BL/6 (F) x
129/sv (M)] were cultured on inactivated mouse
embryonic ﬁbroblasts (MEFs) in DMEM supplemented
with 15% fetal calf serum (FCS), leukaemia-inhibiting
factor, penicillin/streptomycin, L-glutamine and non-
essential amino acids. Prior to genomic DNA extraction
for Bio-CAP experiments, V6.5 cells were cultured for two
passages under feeder-free conditions on 0.1% gelatin.
Bio-CAP
For each individual Bio-CAP experiment, 25mlo f
NeutrAvidin Agarose Resin (Thermo Scientiﬁc, 29200)
or NeutrAvidin-coated magnetic beads (Thermo
Scientiﬁc, 7815-2104-011150) was washed with BC100
buffer and then incubated with 50ml of 0.5mg/ml
biotinylated hKDM2b-CxxC protein diluted in BC100
buffer (or BC100 buffer alone for ‘beads only’ control)
for 1h at 4 C. The conjugated resin/CxxC protein was
then washed with CAP100 buffer (12.5% glycerol, 0.1%
Triton-x-100, 20mM HEPES pH 7.9 and 100mM NaCl).
Genomic DNA at a concentration of 0.35mg/ml was
sonicated to an average size of 150–250bp using a
Diagenode Bioruptor. Sonicated DNA was then diluted
in CAP100 buffer to a concentration of 16mg/ml and a
100ml input sample was retained. For each Bio-CAP ex-
periment, 500ml of diluted sonicated DNA, corresponding
to a 8mg of DNA (unless otherwise stated), was added to
the conjugated CxxC resin. The DNA and resin were
incubated at 4 C for 1h with gentle mixing. The resin
was then collected by centrifugation at 2000rpm for
3min at 4 C or by magnetization, and the unbound
ﬂowthrough (FT) material was removed. The resin and
any associated DNA was washed twice with 1ml of
CAP100 buffer, before the ﬁrst elution was performed
by adding 50ml of CAP300 (12.5% glycerol, 0.1%
Triton-x-100, 20mM HEPES pH 7.9 and 300mM NaCl)
to the resin and incubating at room temperature for
10min. Following centrifugation or magnetisation, a
50ml elution fraction was carefully collected. The elution
process was repeated using another 50ml of CAP300 and
the 300mM elution fractions were pooled (giving a total
volume of 100ml). Subsequent elutions were performed in
the same way using buffers with 500, 700mM and 1M
NaCl sequentially. Each 100ml elution fraction, together
with 100ml of both the input and FT samples, was puriﬁed
using a PCR puriﬁcation column (Qiagen) and DNA was
eluted in a volume of 50ml.
For real-time quantitative PCR (qPCR) analysis,
Bio-CAP samples were typically diluted 10-fold and 5ml
of this was used per 15ml reaction. Analysis was
performed using Sybr Green (Quantace) on a
Rotor-Gene 6000 (Corbett). Primer sets used for qPCR
are available on request.
For the Bio-CAP spiking experiment, 200bp regions
containing set numbers of CpGs were ampliﬁed from
human genomic DNA. The methylated human probe
was generated by in vitro methylation of the 13 CpG
probe with M.SssI (NEB) and the hydroxymethylated
human probe was generated by amplifying the 13 CpG
probe in a PCR reaction containing 5hmC.
Approximately 10pg of each 200bp probe was added to
8mg of sonicated mouse genomic DNA and the Bio-CAP
assay was then performed in the same way as above. The
200bp human probes were interrogated by qPCR using
primer sets nested within each region. Primer sets are
available on request.
MeDIP
Genomic DNA was sonicated using a Diagenode
Bioruptor to an average size of 250bp. Prior to immuno-
precipitation, DNA blunting, dA overhang addition and
adaptor ligation were completed according to Illumina
library preparation recommendations. Immunopre-
cipitation was performed using 2mg of anti-mC antibody
(Eurogentec) using a general MeDIP protocol (httpo://
www.epigenome-noe.net/WWW/researchtools/protocol
.php?protid=33) with some minor modiﬁcations and was
sequenced as described below.
Bisulﬁte sequencing
Bisulﬁte conversion of DNA was performed using the EZ
DNA Methylation-Gold Kit (Zymo Research).
PCR-ampliﬁed DNA was cloned into pGEM-T Easy
(Promega) and sequenced. Sequenced clones were
analysed using the web-based tool QUMA (http://quma
.cdb.riken.jp/)(21).Primersetsusedforbisulﬁtesequencing
are available on request.
High-throughput sequencing
Bio-CAP DNA was prepared for Solexa 2G sequencing by
blunting the DNA with a mixture of T4 DNA polymerase,
Klenow DNA polymerase and T4 PNK (NEB) according
to manufacturer’s instruction. dA overhangs were then
added and Illumina adapters ligated. Adapter-ligated
DNA was subject to 18 cycles of PCR before size selection
by agarose gel electrophoresis. Ampliﬁed DNA was
puriﬁed using the Qiaquick gel extraction kit (Qiagen).
The puriﬁed DNA was quantiﬁed both with an Agilent
Bioanalyzer and Invitrogen Qubit and diluted to a
working concentration of 10nM prior to sequencing.
Sequencing on a Solexa 2G instrument was carried out
according to the manufacturer’s instructions. Raw
sequencing reads were aligned to the mouse mm9
genome using bowtie (22) retaining only reads that align
to one position in the genome. BAM ﬁles corresponding
to the aligned data were imported into Seqminer
(23) to generate the heat map and scatter plot at CGI
regions.
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A biotinylated CxxC domain recognizes DNA containing
non-methylated CpGs
Based on the limitations inherent to the conventional CAP
technique, we set out to devise a simpliﬁed and more func-
tional CAP-based approach to proﬁle non-methylated
DNA. First, we focussed our efforts on identifying a
high-afﬁnity recombinant CxxC domain fragment and
a suitable solid support resin to afﬁx the afﬁnity module
onto. We previously demonstrated that the histone H3
lysine 36 demethylase KDM2A binds speciﬁcally to
non-methylated CpGs via its CxxC domain and in vivo
this recruits the enzyme to non-methylated CGIs (20).
KDM2B, a closely related H3K36 demethylase, also
possesses a CxxC domain. Multiple sequence alignment
shows conservation of the Zn-coordinating cysteines and
DNA-binding residues in KDM2B suggesting that this
protein will also bind non-methylated DNA. To test this
possibility, recombinant His-tagged KDM2B CxxC
domain (His-CxxC) was expressed in Escherichia coli
and puriﬁed on a nickel-NTA (Ni-NTA) column
(Figure 1A). By EMSA, the His-CxxC protein bound to
a DNA probe that contained non-methylated CpGs
(Figure 1B, left panel), but binding was abrogated when
the probe was in vitro methylated (Figure 1B, right panel).
Interestingly, we noticed that binding of the recombinant
KDM2B CxxC domain to non-methylated DNA
appeared more efﬁcient than a similar construct encom-
passing the KDM2A CxxC domain (unpublished observa-
tions) making this a good candidate fragment around
which to develop a new CAP module. The recombinant
KDM2B CxxC fragment was puriﬁed from E. coli using
an N-terminal His tag. To examine whether the addition
of this tag affects the functionality of the CxxC domain,
we cleaved off the His tag taking advantage of a TEV
protease cleavage site between the His tag and the CxxC
domain (Figure 1A). Interestingly, cleavage of the tag
resulted in increased binding to the non-methylated
probe (Figure 1B, left panel) without compromising its
speciﬁcity for non-methylated DNA. This suggests that
in the context of the recombinant KDM2B CxxC
Figure 1. Generation and characterization of a Bio-CxxC protein. (A) Schematic illustrating recombinant CxxC protein with N-terminal His tag
(His-CxxC). Cleavage with TEV protease removes His tag to give CxxC alone. (B) EMSA demonstrating that His-CxxC and CxxC bind to a DNA
probe containing non-methylated CpGs in a concentration-dependent manner (left panel), and that DNA methylation blocks this binding (right
panel). (C) Schematic illustrating the generation of a CxxC protein with a C-terminal Avi-Tag (CxxC-Avi) and the subsequent reaction catalysed by
the E. coli biotin ligase BirA to give a Bio-CxxC protein. (D) Mass spectrometry analysis of CxxC-Avi protein before (left panel) and after in vitro
BirA reaction (right panel). Expected mass of CxxC-Avi is 18939 Da and Bio-CxxC is 19166 Da.
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binding afﬁnity. Based on these observations, the
KDM2B CxxC domain lacking the N-terminal His tag
appears to be an ideal afﬁnity module for DNA-
containing non-methylated CpG dinucleotides.
CAP requires that the CxxC module be afﬁxed to a solid
support to facilitate afﬁnity capture of non-methylated
DNA. Conventional CAP uses a His tag to bind the
CxxC module to a Ni-NTA-based resin. This linkage is
not ideal as Ni-NTA resin has intrinsic charge properties,
is susceptible to leaching of bound protein in the presence
of metal chelating or reducing agents, and is sensitive
to pH and high salt. To overcome some of the disad-
vantages of a His tag linkage, we instead engineered a
15 amino acid AviTag
TM (GLNDIFEAQKIEWHE)
onto the C-terminus of the KDM2B CxxC fragment (to
give CxxC-Avi, Figure 1C) (24,25). The CxxC-Avi protein
was then in vitro biotinylated using recombinant biotin
ligase BirA, an enzyme that speciﬁcally conjugates biotin
to a lysine residue in the AviTag
TM sequence (Figure 1C).
The introduction of a site-speciﬁc biotin moiety into the
afﬁnity module permitted us to afﬁx the CxxC domain to
an avidin-based solid support. The avidin/biotin linkage is
a signiﬁcant improvement over the His tag linkage used
previously as it is one of the strongest documented
non-covalent interactions between a protein and its
ligand, remaining intact even during stringent washing
and manipulation conditions (26). Mass spectrometry
was used to monitor biotinylation of the CxxC-Avi
protein (Figure 1D). Prior to the in vitro BirA reaction,
a proportion of the CxxC-Avi protein was already
biotinylated exhibiting a mass of  19167 Da (the
expected mass for the biotinylated form of the protein)
as opposed to 18393 Da (the expected mass of the unmodi-
ﬁed protein) (Figure 1D, left panel). This is likely due to
biotinylation of the protein by the endogenous E. coli
BirA ligase system. Importantly, in vitro biotinylation by
BirA yielded a homogeneously biotinylated species
(Figure 1D, right panel). The biotinylated CxxC
(Bio-CxxC) protein bound to a DNA probe containing
non-methylated CpGs with similar afﬁnity to an
Avi-CxxC protein without the biotin moiety (data not
shown). Hence neither the presence of the AviTag
TM nor
the biotin moiety interfered with the DNA-binding
activity of the KDM2B CxxC domain.
Bio-CAP speciﬁcally isolates CGI DNA
There are several avidin/streptavidin-based resins with dif-
ferent features that could function as a solid support to
afﬁx the Bio-CxxC protein. NeutrAvidin, a deglycosylated
derivative of avidin, was chosen based on the fact that it
features a near neutral isoelectric point and therefore
exhibits exceptionally low-non-speciﬁc binding properties
while retaining an extremely high afﬁnity for biotin
(Kd  10
 15M
 1) (27).
To determine whether the bead-immobilized CxxC
protein could speciﬁcally isolate non-methylated DNA,
we used genomic DNA from V6.5 mouse ES cells, a cell
type used previously to study the CGI binding factor
KDM2A (20). Mouse ES cell genomic DNA was ﬁrstly
sonicated to an average length of 200bp. Approximately
8mg of sonicated DNA was added to 25mg of the CxxC
binding module that had been immobilized on 25mlo f
NeutrAvidin beads. The DNA and CxxC resin was then
incubated at 4 C for 1h with gentle mixing to permit
CxxC–DNA complexes to form (Figure 2A). After sedi-
menting the CxxC resin and associated DNA by centrifu-
gation, the unbound FT DNA was collected. Material that
bound to the CxxC domain was then subjected to a series
of sequential elution steps using increasing salt concentra-
tions and fractions were collected at each salt concentra-
tion (300, 500, 700mM and 1M NaCl) (Figure 2A).
DNA from the input, FT and each of the elution frac-
tions was subjected to quantitative PCR (qPCR) using
primer sets speciﬁc to the Suv420h1 promoter CGI and
gene body. This analysis revealed that DNA correspond-
ing to the Suv420h1 CGI was mostly present within the
high-salt fractions (700mM and 1M), with little or none
of the Suv420h1 CGI present in the FT and low-salt
(300mM) fractions (Figure 2B). In contrast, DNA corres-
ponding to the Suv420h1 gene body was mostly present
within the FT and low-salt fractions, with almost no DNA
from this region present in the high-salt fractions
(Figure 2B, left panel). Similar qPCR analysis was also
performed using promoter and body primer sets from
Fabp7, a gene that lacks a CGI at its promoter. While
the Fabp7 body region has an elution proﬁle almost iden-
tical to that of the Suv420h1 body, unlike Suv420h1, the
Fabp7 promoter region eluted mostly in the low-salt frac-
tions indicating a lack of non-methylated CpG dinucleo-
tides (Figure 2C, left panel). To verify that these elution
proﬁles were dependent speciﬁcally upon the CxxC
domain, a control experiment was performed using
NeutrAvidin beads alone. In the beads only experiment,
DNA corresponding to both the promoter and body
regions of Suv420h1 and Fabp7 was exclusively present
within the FT fraction demonstrating that the
NeutrAvidin solid support exhibits no non-speciﬁc DNA
binding (Figure 2B and C, right panels).
From the above analyses, it was evident that the
high-salt fractions exhibited massive enrichment of the
Suv420h1 CGI compared to non-CGI regions. In order
to understand whether this holds true for other regions
of the genome, we designed promoter and body primer
sets for a panel of genes with CGI promoters
(Figure 2D), and genes with non-CGI promoters
(Figure 2E). Each of these primer sets was used to assay
the high-salt fractions from our CxxC-based puriﬁcation
by qPCR. These experiments demonstrate that in all cases
the high-salt elution fractions (a sum of 700mM and 1M
fractions) are massively enriched for CGIs (Figure 2D and
E), with non-CGI regions exhibiting negligible enrich-
ment. In silico algorithms have previously been used to
predict the presence of CGIs, but these often overlook
some regions that actually exhibit signiﬁcant levels of
non-methylated CpGs. One such example is the
promoter of the Fastkd2 gene, which was shown by a
CAP-sequencing study to be non-methylated in mouse
sperm yet is not bioinformatically deﬁned as a CGI (19).
Consistent with this previous observation, the Fastkd2
promoter is strongly enriched in the high-salt fractions
PAGE 5 OF 14 Nucleic AcidsResearch, 2012, Vol.40,No. 4 e32Figure 2. Bio-CAP speciﬁcally puriﬁes CGI DNA. (A) Schematic of the Bio-CAP procedure. The immobilized Bio-CxxC protein is ﬁrst incubated
with sheared genomic DNA, allowing DNA to bind to the CxxC domain. The unbound FT is then collected, followed by a series of elution fractions
performed at increasing salt concentrations. DNA from each of these fractions is then interrogated by qPCR or massively parallel sequencing.
(B) Analysis of Suv420h1, a gene with a CGI promoter, in a Bio-CAP experiment (left panel) or a ‘beads only’ control experiment (right panel). For
both experiments, DNA from each fraction was subjected to qPCR using primer sets speciﬁc to the CGI promoter (blue) or body region (red) of
Suv420h1.( C) As for (B) except that primer sets were speciﬁc to the promoter and body of Fabp7, a gene that has a non-CGI promoter.
(D) Bio-CAP analyses for a panel of genes with CGI promoters. Promoter and body primer sets were used to assay the CGI-enriched fractions
(700mM+1M) from a Bio-CAP assay. A schematic of each gene showing the position of primer sets and CGI from in silico predictions is shown
above each data set. (E) As for (D) except primer sets were speciﬁc to a panel of genes with non-CGI promoters. All Bio-CAP data are from two
biological replicates and error bars represent SEM.
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non-methylated in mouse ES cells (Figure 2D, far right
panel). Collectively, these analyses demonstrate that
within the context of our CxxC-based afﬁnity puriﬁcation,
regions of the genome corresponding to CGIs are specif-
ically retained with high afﬁnity, eluting only under
high-salt conditions. In contrast, non-CGI regions are
not retained by the immobilized CxxC domain and are
therefore present in the FT and low-salt elutions.
Therefore, using our new afﬁnity matrix and scaled-down
CAP conﬁguration we demonstrate simple, robust and
speciﬁc isolation of non-methylated DNA. Based on the
utilization of a biotinylated high-afﬁnity CxxC domain,
we call this new puriﬁcation strategy Bio-CAP.
Bio-CAP elution proﬁles are dictated by methylation
status and density of CpGs
The above experiments demonstrate that the high-salt
elutions of the Bio-CAP assay speciﬁcally represent the
CGI fraction of the genome. Although the majority of
CGIs remain free of DNA methylation, at certain
developmental time points or in particular disease states-
speciﬁc CGIs can acquire DNA methylation. To investi-
gate the impact of DNA methylation on the CGI elution
proﬁles within Bio-CAP, we took advantage of the Gnas
CGI, which is subject to an allele-speciﬁc epigenetic
imprinting process that results in dense methylation of
the CGI on the maternal allele while the paternal allele
remains non-methylated (28). Using bisulﬁte sequencing
analysis, this imprinting was conﬁrmed for the mouse
ES cells used in our Bio-CAP experiments, with the
expected 50:50 ratio of non-methylated to methylated
alleles (Figure 3A). Using qPCR analysis, we then went
on to quantify the presence of the Gnas CGI in Bio-CAP
fractions. This revealed a relatively ﬂat elution proﬁle,
with comparable amounts of the Gnas CGI in the FT,
300, 500 and 700mM fractions (Figure 3B). This is in
contrast to typical CGI elution proﬁles that demonstrate
negligible presence in the FT and low-salt (300mM) frac-
tions, with massive enrichment in the high-salt fractions
(especially 700mM) (compare Figure 2B with Figure 3B).
To determine the methylation status of the Gnas CGI in
each of the Bio-CAP fractions, material from each
fraction was subjected to bisulﬁte sequencing. This
revealed that the FT and 300mM Bio-CAP fractions
contained only the methylated Gnas allele, while the 500,
700mM and 1M fractions contained only the
non-methylated Gnas allele (Figure 3C). This striking
result demonstrates that within the context of a Bio-
CAP assay, the methylation status of a CGI dictates its
binding afﬁnity for the CxxC domain. Bio-CAP is there-
fore able to separate methylated CGIs from non-
methylated CGIs.
Various computational algorithms based on CpG
observed/expected ratio and GC percentage have been
used to predict CGI genomic locations (5). However, it
has since been experimentally shown that some regions
of non-methylated DNA fall below the CpG and/or GC
threshold required for in silico deﬁnition as a CGI (19).
To determine how CpG density inﬂuences Bio-CAP
read-out, primers were designed to speciﬁcally amplify
200bp regions of the human genome containing speciﬁc
numbers of CpG dinucleotides (0, 2, 6, 13 and 24 CpGs).
Mouse ES cell genomic DNA was spiked using each of
these 200bp human probes, such that each probe was at
approximately the same molar concentration as the mouse
genomic DNA, and this spiked DNA mixture was then
used in a Bio-CAP experiment. The spiked Bio-CAP frac-
tions were interrogated using primer sets nested within
each individual 200bp probe, therefore revealing the
elution proﬁle for each human fragment (Figure 3D).
Unsurprisingly, the 200bp probe containing 0 CpGs was
exclusively present in the FT and 300mM fractions,
indicating no speciﬁc binding of this probe to the CxxC
domain. However, with increasing numbers of CpGs, the
200bp probes exhibited elution proﬁles that shifted
towards the higher salt elutions, indicating speciﬁc
binding by the CxxC domain. Importantly, there was a
near-linear relationship between the number of
non-methylated CpGs and the percentage recovery in
the high salt (700mM and 1M) fractions (Figure 3E).
This would imply that by interrogating high salt
Bio-CAP fractions, one gets a semiquantitative read-out
of the absolute number of non-methylated CpGs present
in a given DNA fragment. Importantly, this experiment
also demonstrates that Bio-CAP is able to reveal the
presence of non-methylated DNA, even when these
regions fall below the threshold for traditional computa-
tional CGI deﬁnition. This is illustrated well by the 200bp
probe with six CpGs, which does not have the CpG
density necessary for computational deﬁnition as a CGI,
yet shows moderate recovery in the high salt Bio-CAP
elutions (Figure 3D and E). To assay the impact of
DNA methylation on recovery of 200bp human probes,
the 13 CpG probe was in vitro methylated. This resulted in
complete abrogation of recovery in the high-salt fractions
(Figure 3F), further demonstrating that methylation of
CpGs inhibits CxxC domain binding. It has been
recently shown that a small proportion of CpGs within
the genome are hydroxymethylated (29,30). Importantly,
a hydroxymethylated version of the 13 CpG probe also
demonstrated negligible recovery in the Bio-CAP high-salt
fractions (Figure 3F), indicating that within the context of
a Bio-CAP experiment, the CxxC domain does not recog-
nize hydroxymethylated CpGs. Collectively, these experi-
ments using the imprinted Gnas CGI and spiking with
human DNA probes demonstrate that speciﬁc retention
of DNA in Bio-CAP assays is dictated by the density
of CpGs within a given genomic region and is
negatively impacted by both CpG methylation and
hydroxymethylation.
As with other afﬁnity-based techniques (such as MeDIP
or MethylCap), Bio-CAP is dependent on the number of
CpGs available for binding. Hence, it is difﬁcult to quan-
titatively compare the absolute level of non-methylated
DNA between two regions with differential CpG
density. Nevertheless, a speciﬁc locus can be directly
compared between samples for changes in methylation
status.
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from small quantities of DNA and can be adapted for
high-throughput approaches
The conventional CAP technique uses a chromatography
column conﬁguration with large elution volumes (3ml),
meaning that prior to analysis by qPCR or massively
parallel sequencing, puriﬁed CAP DNA must be
concentrated by precipitation (18). Due to the large
column volumes and precipitation step at which signiﬁ-
cant loss of DNA can occur, this CAP technique
requires sizeable quantities of input DNA per puriﬁcation
( 100mg) (18). A requirement for such large quantities of
input material limits the utility of conventional CAP in
instances when DNA availability is limiting, such as very
small or precious biological samples. For example, within
a clinical setting, if one wanted to study the DNA methy-
lation status of patient samples, obtaining large quantities
of DNA for this purpose could be problematic. Unlike
conventional CAP, the Bio-CAP assay uses small
quantities of beads (25ml) that have very low-non-speciﬁc
binding properties and small elution volumes (2  50mla t
each salt concentration). We therefore hypothesized that
Bio-CAP may be amenable to much smaller amounts of
input DNA than conventional CAP. To examine this pos-
sibility, Bio-CAP assays were performed using 100ng of
mouse ES cell DNA. The high-salt elutions were
Figure 3. Bio-CAP is sensitive to the methylation status and density of CpG dinucleotides. (A) A schematic of the imprinted Gnas gene, which has a
CGI promoter that is methylated on the maternal allele but non-methylated on the paternal allele (left panel). Using the indicated bisulﬁte
PCR amplicon (BA), this imprinting was conﬁrmed in the mouse ES cells used for Bio-CAP (right panel). Empty and ﬁlled circles represent
non-methylated and methylated CpG dinucleotides, respectively. (B) qPCR analysis of Gnas promoter and body regions in Bio-CAP. A schematic
of Gnas indicating the position of primer sets and a CGI from in silico prediction is shown above the data set. (C) Using the same amplicon
(BA) shown in (A), bisulﬁte sequencing was performed on each of the fractions from a Bio-CAP experiment. (D) A Bio-CAP experiment with mouse
ES cell DNA was spiked with a panel of human-speciﬁc 200bp probes each containing a known number of CpGs. Using qPCR analysis, Bio-CAP
fractions were assayed for the presence of each probe. (E) Scatter graph showing relationship between number of CpGs and % input recovery in
high-salt fractions (700mM+1M) of Bio-CAP spiking experiment shown in (D). A line of best ﬁt is shown. (F) A Bio-CAP experiment with mouse
ES cell DNA was spiked with a 200bp human probe containing 13 CpGs that were either unmodiﬁed, methylated (5mC) or hydroxymethylated
(5hmC). Using qPCR analysis, Bio-CAP high-salt fractions (700mM+1M) were assayed for the presence of each of probe variant. All Bio-CAP
data are from at least two biological replicates and error bars represent SEM.
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primer sets for Suv420h1 and Ncoa2, two genes with
non-methylated CGI promoters. These analyses revealed
that the CGI promoter regions of both genes were mas-
sively enriched compared to the corresponding gene body
regions (Figure 4A). Similar qPCR analysis was per-
formed using promoter and body primer sets speciﬁc for
Fabp7 and Fgf7, genes that lack CGIs at their promoters.
These analyses revealed little or no enrichment for either
non-CGI promoter relative to the corresponding gene
body (Figure 4B). Strikingly, the absolute percentage
recovery values from the Bio-CAP assay with 100ng
input DNA are almost identical to the percentage
recovery values for Bio-CAP using 8mg input DNA
(compare Figure 4A and B with Figure 2D and E). The
Bio-CAP assay is therefore extremely robust and yields
consistent recovery, even when the amount of input
DNA between samples differs by almost two orders of
magnitude.
For reasons discussed above, including chromatog-
raphy processing time and extensive DNA handling
steps, the conventional CAP technique is somewhat la-
borious in nature. By comparison, Bio-CAP is simpler,
scaled down and streamlined. These features mean that
Bio-CAP is amenable to parallel processing of multiple
samples. Recently, systems such as the Diagenode
SX-8G IP-Star Compact that rely on magnetic separ-
ation of samples have been used for puriﬁcation of
methylated DNA (16). Therefore, to test whether Bio-
CAP could be adapted for use in a magnetic conﬁgur-
ation, we performed a modiﬁed Bio-CAP assay in which
the Bio-CxxC domain was immobilized on
NeutrAvidin-coated magnetic particles. Mouse genomic
DNA sonicated to 150–250bp was incubated with the
magnetic CxxC resin for 1h in the same way as a
regular Bio-CAP experiment. The magnetic CxxC resin
and associated DNA were then collected using a
magnetic microcentrifuge tube rack, allowing unbound
FT material to be removed. To further streamline the
Bio-CAP procedure in this magnetic approach, two
10min washes were performed in 500mM NaCl to
remove non-speciﬁcally bound material, followed by two
10min elution steps in 1M NaCl. Using this streamlined
magnetic Bio-CAP approach, the entire puriﬁcation
procedure, including pull down, washes, elutions and
DNA clean-up takes  2h. The 1M elutions from the
magnetic Bio-CAP assay were analysed by qPCR, using
the same CGI and non-CGI primer sets as above.
Figure 4. Bio-CAP can be performed on low quantities of DNA and can be adapted for magnetic bead-based automation. (A) Bio-CAP was
performed using 100ng of mouse ES cell DNA and the high-salt fractions (700mM+1M) were interrogated by qPCR using promoter and body
primer sets speciﬁc to two genes with CGI promoters. A schematic of each gene showing the position of primer sets and CGI from in silico
predictions is shown above each data set. (B) As for (A) except that primer sets were speciﬁc to two genes with non-CGI promoters. (C) A Bio-CAP
experiment was performed using NeutrAvidin-coated magnetic beads and the high-salt fractions (700mM+1M) were interrogated by qPCR using
promoter and body primer sets speciﬁc to two genes with CGI promoters. (D) As for (C) except that primer sets were speciﬁc to two genes with
non-CGI promoters. All Bio-CAP data are from two biological replicates and error bars represent SEM.
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identically the Bio-CAP assay with conventional
NeutrAvidin beads (compare Figure 4C and D with
Figure 4A and B), with CGI regions being massively
enriched in the high-salt fraction compared to gene body
and non-CGI promoter regions. This simpliﬁed magnetic
recovery approach allows manual parallel processing of
samples with a typical magnetic microcentrifuge rack
capable of manipulating 16 samples per run. These experi-
ments demonstrate that Bio-CAP can be used in conjunc-
tion with NeutrAvidin-coated magnetic particles to rapidly
and speciﬁcally purify non-methylated DNA. Using this
magnetic particle approach, it is likely that Bio-CAP
would easily transit to an automated puriﬁcation system
such as the Diagenode SX-8G IP-Star Compact further
reducing hands on time and increasing throughput.
Bio-CAP can be coupled to massively parallel sequencing
to proﬁle non-methylated DNA
In all of the above analyses, we interrogated Bio-CAP
material via qPCR with primer sets speciﬁc for individual
genomic loci. We were also keen to understand whether
Bio-CAP can be utilized for genome-wide proﬁling of
non-methylated DNA. The conventional CAP technique
has been previously coupled to massively parallel
sequencing to map non-methylated CGIs in genomic
DNA from mouse sperm (19), providing a comparative
measure for application of Bio-CAP for the same purpose
(Bio-CAP-seq). Starting with 8mg of mouse sperm genomic
DNA, the Bio-CAP high-salt fractions (700mM and 1M)
yielded  120ng of puriﬁed DNA, of which 10ng was used
forlibrary generationandSolexa 2G sequencing. When the
Bio-CAP-seq reads were aligned to the mouse genome
(complete data set to be published at a later date), huge
enrichment was observed at computationally deﬁned
CGIs (Figure 5A). Importantly, non-CGI gene promoters
showed little or no enrichment, conﬁrming that Bio-CAP
speciﬁcally captures regions containing non-methylated
CpGs rather than promoter elements per se. Focussing on
contiguous regions of the genome, the proﬁle for
non-methylated DNA obtained by Bio-CAP-seq shows a
strikingcorrelationwiththeexistingconventionalCAP-seq
data set for mouse sperm (Figure 5). This striking correl-
ation holds true when Bio-CAP-seq and CAP-seq are
compared at CGIs genome wide (Figure 5B and C). We
also observed that peaks in the Bio-CAP sequencing
proﬁle show extremely good overlap with sites of enrich-
ment for the CGI binding factor KDM2A obtained from
mouse ES cells (20) (Figure 5A). Importantly, an input
DNA control sample, which gave a similar number of
sequencing reads, resulted in a ﬂat sequencing proﬁle
with no enrichment at CGI regions (Figure 5A). These
analyses demonstrate that Bio-CAP can be coupled with
massively parallel sequencing to proﬁle non-methylated
DNA genome wide.
Bio-CAP-seq speciﬁcally and efﬁciently identiﬁes
non-methylated DNA
Techniques based on afﬁnity capture of methylated DNA,
notably MeDIP and MethylCap, have been previously
coupled to massively parallel sequencing to proﬁle
methylated CpGs genome wide (15,16,31,32). Using
mouse ES cell genomic DNA, we performed Bio-CAP-
seq and MeDIP-seq in order to highlight the utility of
Bio-CAP for non-methylated CGI identiﬁcation and to
verify that these regions generally lack methylated DNA
signal. When visualizing Bio-CAP-seq and MeDIP-seq
signals at equivalent read depth, non-methylated CGIs
are immediately evident in the Bio-CAP-seq proﬁles, but
difﬁcult to identify in the MeDIP-seq proﬁles (Figure 6A
and B). Although non-methylated regions can be compu-
tationally inferred from MeDIP-seq data sets, this often
requires increased sequencing depth and usually fails to
identify non-methylated regions with a low-CpG density
(33). Indeed, it was only with the advent of CAP that the
large number of non-methylated regions falling below
the CGI algorithm threshold became evident (18).
Importantly, by comparing Bio-CAP-seq and MeDIP-
seq signal at CGIs genome wide there was no correlation
between Bio-CAP-seq signal and MeDIP-seq signal,
verifying that Bio-CAP-seq effectively identiﬁes non-
methylated regions of the genome (Figure 6C). Together
these observations highlight the utility of Bio-CAP-seq for
identiﬁcation of non-methylated DNA.
DISCUSSION
Within mammalian genomes, the methylation status of
CpG dinucleotides can impact gene expression and has
been implicated in various developmental and disease
processes. Techniques to study DNA methylation
include the recently developed CAP approach to speciﬁc-
ally capture regions of DNA containing non-methylated
CpGs. The CAP assay takes advantage of a CxxC domain
that speciﬁcally binds non-methylated (but not
methylated) CpG dinucleotides. Although CAP has been
successfully used to map non-methylated CGIs in a variety
of cell types from different species (18,19), the technique
has some limitations. Notably, the chromatography
column-based approach requires specialist equipment
that some laboratories may not have access to, while
large elution volumes result in extensive, time-consuming
DNA handling steps and demand sizable amounts of
input DNA.
To overcome the limitations inherent to the convention-
al CAP assay, we have developed a new CxxC-based puri-
ﬁcation called Bio-CAP. Bio-CAP exploits a high-afﬁnity
CxxC domain from the histone H3 lysine 36 demethylase
KDM2B, into which we have engineered a biotin moiety.
This biotin tag enables the CxxC module to be
immobilized with a high afﬁnity onto an avidin-based
solid support. The nature of this interaction, together
with the choice of solid support resin, means that the
entire Bio-CAP procedure, including pull-down, washes
and elution steps, can be performed in standard
microcentrifuge tubes. When compared to conventional
CAP, the Bio-CAP procedure is therefore much simpler,
requiring only standard laboratory equipment.
Furthermore, unlike conventional CAP, the Bio-CAP
technique is amenable to processing multiple samples in
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automation.
Importantly, we have demonstrated that Bio-CAP can
be coupled to qPCR to assay non-methylated DNA at
individual loci, or to massively parallel sequencing
(Bio-CAP-seq) to proﬁle non-methylated DNA genome
wide. Techniques based on afﬁnity capture of methylated
CpGs, such as MeDIP, suffer from a reduced capacity to
detect non-methylated genomic regions that have a
low-CpG density (33). In contrast, traditional CAP and
now Bio-CAP are able to enrich for non-methylated
DNA, even at low-CpG density, enabling sensitive
proﬁling of non-methylated CGIs (18). We anticipate
that identiﬁcation of non-methylated CGIs using
Bio-CAP-seq, as opposed to inferring their location
from extensive sequencing of the large methylated
genomic fraction (by MeDIP-seq, for example), will
improve our capacity to accurately identify non-
methylated regions of the genome, particularly in
regions with low-CpG density.
Bio-CAP recovers DNA fragments with an efﬁciency
that is directly proportional to the density of
non-methylated CpGs and speciﬁcally discriminates
between methylated and non-methylated CGIs.
Furthermore, in a signiﬁcant advance on the conventional
CAP assay, Bio-CAP can be performed on nanogram
quantities of DNA without any apparent loss of reso-
lution. We therefore envisage that Bio-CAP could be
Figure 5. Bio-CAP followed by massively parallel sequencing reveals non-methylated CGIs genome wide. (A) The high-salt fraction (700mM+1M)
from a Bio-CAP experiment with mouse sperm genomic DNA was subjected to massively parallel sequencing and sequencing reads were aligned back
to the mouse genome. Bio-CAP sequencing analysis is shown (top panel, red) for an  180kb region of chromosome 3 (chr3: 103598131–
103782151), with comparative analysis from conventional CAP sequencing (second panel, light blue), KDM2A ChIP sequencing in mouse ES
cells (third panel, black) and input material (bottom panel, dark blue). Annotated genes in this region are illustrated above the sequencing traces,
with arrows indicating transcription start sites and CGIs from in silico predictions indicated in green. (B) Heat map comparing CAP-seq and
Bio-CAP-seq data sets centered at CGIs including 5kb windows upstream and downstream. (C) Bio-CAP-seq enrichment plotted against CAP-seq
enrichment for all CGIs genome wide, illustrating the extremely high correlation between Bio-CAP-seq and CAP-seq.
PAGE 11 OF 14 Nucleic AcidsResearch, 2012, Vol.40,No. 4 e32Figure 6. Comparison with MeDIP-seq reveals the utility of Bio-CAP-seq in identifying non-methylated CGIs. (A) Mouse ES cell genomic DNA
was subjected to both Bio-CAP-seq and MeDIP-seq. Aligned sequencing data are shown for Bio-CAP-seq (top panel, red), MeDIP-seq (middle
panel, green) and matched input material (bottom panel, blue) for an  180kb region of chromosome 3 (chr3: 103598131–103782151). Annotated
genes in this region are illustrated above the sequencing traces, with arrows indicating transcription start sites and CGIs from in silico predictions
indicated in green. (B) Bio-CAP-seq and MeDIP-seq data for another three genic regions, each including a CGI. The ﬁgure is annotated as for (A).
(C) Bio-CAP-seq enrichment plotted against MeDIP-seq enrichment for all CGIs genome wide. The plot demonstrates that Bio-CAP-seq and
MeDIP-seq exhibit no correlation, consistent with the fact that Bio-CAP-seq identiﬁes non-methylated regions of the genome.
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number of biological scenarios, both at speciﬁc loci and
genome wide. This could include situations in which only
small amounts of DNA are available, potentially allowing
CGI methylation status proﬁling in rare subpopulations of
cells, at very early stages of development, or in valuable
experimental samples. Due to the sensitivity of Bio-CAP,
we also believe that this technique could reveal subtle
methylation differences between samples, for example dif-
ferent developmental time points or different disease
states. Finally, given its sensitivity and capacity for
robotic automation, it is possible that Bio-CAP could be
used in diagnostic applications.
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